Notable Upgrades: Apple Inc. (AAPL), Coronado Biosciences (CNDO), Pioneer Energy (PES), ImmunoGen (IMGN), Ultragenyx (RARE), Rigel (RIGL)

Apple Inc. (AAPL) was reiterated a ‘Outperform’ by RBC Capital Markets analysts on Tuesday. The broker also raised its price target on the stock to $142 from $140.

On valuation measures, Apple Inc. shares are currently priced at 16.96x this year’s forecasted earnings compared to the industry’s 25.43x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.13 and 13.42, respectively. Price/sales for the same period is 3.68 while EPS is $7.39. Currently there are 33 analysts that rate AAPL a ‘Buy’, 11 rate it a ‘Hold’. 2 analysts rate it a ‘Sell’. AAPL has a median Wall Street price target of $145.00 with a high target of $180.00.

In the past 52 weeks, shares of the Sunnyvale, California-based tech giant have traded between a low of $73.05 and a high of $133.60 and are now at $125.26. Shares are up 67.89% year-over-year and 14.93% year-to-date.

Analysts at MLV & Co. are out with a report this morning upgrading shares of Coronado Biosciences, Inc. (CNDO) with a ‘Buy‘ from ‘Hold‘ rating. The firm raised its price target for the company to $7 from $2, implying 250% upside.

During today’s session, Coronado Biosciences, Inc. printed a higher than average trading volume with the issue trading 2.8 million shares, compared to the average volume of 879K. The stock began trading this morning at $3.75 to currently trade nearly 14% higher from the prior days close of $3.54. On an intraday basis it has gotten as low as $3.75 and as high as $4.39.

Coronado shares have advanced 37.74% in the last 4 weeks and 59.46% in the past three months. Over the past 5 trading sessions the stock has lost 10.15%. Shares are up 45.08% this year.

Analysts at Wells Fargo (WFC) upgraded their rating on the shares of Pioneer Energy Services Corp. (PES). In a research note published on Tuesday, the firm lifted the name with a ‘Outperform‘ from ‘Market Perform‘ rating.

On valuation measures, Pioneer Energy Services Corp. shares have PEG ratio of -0.66. Price/sales for the same period is 0.30 while EPS is ($0.60). Currently there are 2 analysts that rate PES a ‘Buy’, 10 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. PES has a median Wall Street price target of $5.50 with a high target of $8.00.

ImmunoGen, Inc. (IMGN) was raised to ‘Buy‘ from ‘Hold‘ and it was given a $12 from $9 price target at Cantor Fitzgerald on Tuesday.

IMGN is up $0.55 at $9.07 on heavy volume. Midway through trading Tuesday, 3.58 million shares of Immunogen Inc. have exchanged hands as compared to its average daily volume of 1.35 million shares. The stock ranged in a price between $8.76-$9.54 after having opened the day at $8.89 as compared to the previous trading day’s close of $8.52.

In the past 52 weeks, shares of Waltham, Massachusetts-based company have traded between a low of $5.34 and a high of $15.59. Shares are down 42% year-over-year and 39.67% year-to-date.

Investment analysts at MLV & Co. initiated coverage on shares of Ultragenyx Pharmaceutical Inc. (RARE) in a note issued to investors on Tuesday. The firm set a ‘Buy’ rating and a $79 price target on the stock. The firm’s price target would suggest a potential upside of 28% from the stock’s current price of $61.79.

Currently there are 7 analysts that rate RARE a ‘Buy’. No analyst rates it a ‘Hold’ or a ‘Sell’. RARE has a median Wall Street price target of $75.00 with a high target of $90.00.

In the past 52 weeks, shares of Novato, California-based clinical-stage biopharmaceutical company have traded between a low of $32.02 and a high of $65.35. Shares are up 33.40% year-over-year and 38.90% year-to-date.

Rigel Pharmaceuticals, Inc. (RIGL) coverage was resumed on Tuesday by Jefferies with a ‘Buy’ rating and a valuation of $10.

RIGL shares recently gained $0.39 to $3.74. In the past 52 weeks, shares of South San Francisco, Calif.-based firm have traded between a low of $1.56 and a high of $4.20. Shares are down 12.53% year-over-year ; up 47.58% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*